Prevention of RSV disease in babies starts at HUS hospitals
11.10.2024 11:43:23 EEST | HUS | Press release
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody developed against the RS virus called nirsevimab to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is offered to all children born after August 1, 2024. HUS will offer nirsevimab to newborns in all its maternity hospitals from October 23, 2024. Children under the age of one year at risk for severe disease will be offered nirsevimab at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 4, 2024, until the end of November.
The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024
Nirsevimab is effective in preventing RSV infections
A long-acting antibody called nirsevimab is used to prevent RSV infections. It is administered as a single intramuscular injection. Nirsevimab is safe to administer even to newborns, and it provides efficient protection against RSV for the entire winter epidemic.
The product is very safe. It has been in use in several countries during the winter 2023–2024, where it prevented 80–90% of hospitalizations caused by RSV.
Keywords
Contacts
Director Jari Petäjä, p. 050 428 6630, jari.petaja@hus.fi
HUS Children and adolecents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-sammanslutningens styrelse sammanträder 2.3.26.2.2026 15:08:43 EET | Pressmeddelande
Sammanslutningens styrelse sammanträder den 2 mars 2026 för att bland annat behandla HUS-sammanslutningens oreviderade bokslutsuppgifter för 2025 samt verksamheten och ekonomin i januari 2026. Föredragningslistan för mötet kan läsas här. Sammanslutningens styrelse leder HUS verksamhet, förvaltning och ekonomi. Sammanslutningsstyrelsen har 17 medlemmar, varav två är representanter för Helsingfors universitet. Sammanslutningens styrelse sammanträder cirka en gång i månaden. HUS medietjänst betjänar medier måndag–torsdag kl. 10–16, fredag kl. 10–15 på numret 050 427 2875 eller per e-post på viestinta@hus.fi. Se avvikande öppettider.
HUSin yhtymähallitus kokoontuu 2.3.26.2.2026 15:08:43 EET | Tiedote
Yhtymähallitus kokoontuu 2. maaliskuuta 2026 käsittelemään muun muassa HUS-yhtymän vuoden 2025 tilintarkastamattomia tilinpäätöstietoja sekä tammikuun 2026 toimintaa ja taloutta. Kokouksen esityslistan voi lukea täältä. Yhtymähallitus johtaa HUSin toimintaa, hallintoa ja taloutta. Yhtymähallituksessa on 17 jäsentä, joista kaksi on Helsingin yliopiston edustajia. Yhtymähallitus kokoontuu noin kerran kuukaudessa. HUSin mediapalvelu palvelee mediaa ma–to klo 10–16, pe klo 10–15 numerossa 050 427 2875 tai sähköpostitse viestinta@hus.fi. Katso poikkeusaukioloajat
HUS klättrade i rankingen över världens bästa sjukhus26.2.2026 14:16:35 EET | Pressmeddelande
HUS placerade sig på plats 40 i Newsweeks bedömning av världens bästa sjukhus 2026. HUS förbättrade sin placering för andra året i rad och är i denna jämförelse det klart högst rankade sjukhuset i Finland.
HUS nosti sijoitustaan maailman parhaiden sairaaloiden listauksessa26.2.2026 14:16:35 EET | Tiedote
HUS sijoittui Newsweekin vuoden 2026 maailman parhaiden sairaaloiden arvioinnissa sijalle 40. HUS paransi sijoitustaan listalla toista vuotta peräkkäin ja on kirkkaasti Suomen parhaaksi arvioitu sairaala tässä vertailussa.
Komjölksallergi i tidig barndom har samband med nedsatt bentäthet i ungdomen23.2.2026 08:29:14 EET | Pressmeddelande
En studie visar att komjölksallergi som konstaterats i spädbarnsåldern har samband med nedsatt bentäthet i ungdomen, även om allergin hos största delen av barnen hade försvunnit före puberteten. Nedsatt bentäthet kan öka risken för frakturer.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom